A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Ipglycermides are a class of non-natural macrocyclic peptide (MCP) inhibitors that target cofactor-independent phosphoglycerate mutases (iPGMs). The activity of human phosphoglycerate mutase requires the cofactor 2,3-bisphosphoglycerate (dPGM), whereas a structurally unrelated isozyme found in many parasitic species functions without a cofactor (iPGM). This variation in mechanism and evolutionary origin presents a potential drug target for selectively inhibiting glycolysis in pathogenic organisms. Specifically, they have shown promise in fighting filarial (round worm) diseases such as those caused by Brugia malayi, Onchocerca volvulus, and Dirofilaria immitis (heartworm). Ipglycermides are composed of 14 amino acids and contain an 8-membered macrocycle formed through a thioether bridge connecting the D-Tyr1 α-acetamide and Cys8 sulfhydryl side chain. Compared to most small-molecule drugs, there are more interactions with the drug target that allow them to work at significantly lower concentrations.
=== Off-label drugs === Antipsychotics (non-selective monoamine receptor modulators) (e.g., olanzapine, quetiapine, risperidone) Benzodiazepines (GABAA receptor positive allosteric modulators) (e.g., alprazolam, clonazepam, diazepam, lorazepam) Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, sotalol) Cannabinoids (cannabinoid receptor agonists) (e.g., cannabis, THC/dronabinol, nabilone) Lamotrigine (sodium channel blocker, other actions) Monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine) NMDA receptor antagonists (dissociative hallucinogens) (e.g., ketamine, esketamine) Other selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, escitalopram, fluoxetine, fluvoxamine) Prazosin (α1-adrenergic receptor antagonist) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., desvenlafaxine, duloxetine, milnacipran, venlafaxine) Topiramate (various actions) Tricyclic antidepressants (TCAs) (e.g., imipramine, amitriptyline)
== Occurrence == It occurs in tree fern fronds, a specialty called fiddlehead (furled fronds of a young tree fern in the order Cyatheales, harvested for use as a vegetable). These fronds are edible, but can be roasted to remove shikimic acid. Shikimic acid is also the glycoside part of some hydrolysable tannins. The acid is highly soluble in water and insoluble in nonpolar solvents, and this is why shikimic acid is active only against Gram-positive bacteria, due to outer cell membrane impermeability of Gram-negatives.
=== ICD-11 === The eleventh revision of the International Classification of Diseases, commonly referred to as ICD-11, conceptualizes diagnosis somewhat differently. ICD-11 first distinguishes between problems with psychoactive substance use ("Disorders due to substance use") and behavioral addictions ("Disorders due to addictive behaviours"). With regard to psychoactive substances, ICD-11 explains that the included substances initially produce "pleasant or appealing psychoactive effects that are rewarding and reinforcing with repeated use, [but] with continued use, many of the included substances have the capacity to produce dependence. They have the potential to cause numerous forms of harm, both to mental and physical health." Instead of the DSM-5 approach of one diagnosis ("Substance Use Disorder") covering all types of problematic substance use, ICD-11 offers three diagnostic possibilities: 1) Episode of Harmful Psychoactive Substance Use, 2) Harmful Pattern of Psychoactive Substance Use, and 3) Substance Dependence.
Sources: en.wikipedia.org
Some notable analogues of DFMDA include DFMDMA (F2-MDMA), EIDA, and IDA, among others. Other fluorinated MDxx derivatives, for instance derivatives of MDEA, BDB, and MBDB, have also been described. DFMDA was first described in the scientific literature by Daniel Trachsel and colleagues in 2006. He described its properties and effects in humans in 2012 and 2013.
== Conferences == The society's annual meeting is held in the first week of September as well as regular special interest group meetings (Lipidomics, MALDI & Imaging, Ambient Ionisation, Environmental & Food Analysis) through the year, in locations throughout the United Kingdom. Locations of the society's annual meetings beginning in 1965:
Risperidone has been classified as a "qualitatively atypical" antipsychotic agent with a relatively low incidence of extrapyramidal side effects (when given at low doses) that has more pronounced serotonin antagonism than dopamine antagonism. Risperidone contains the functional groups of benzisoxazole and piperidine as part of its molecular structure. Although not a butyrophenone, it was developed with the structures of benperidol and ketanserin as a basis. It has actions at several 5-HT (serotonin) receptor subtypes. These are 5-HT2C, linked to weight gain, and 5-HT2A, linked to its antipsychotic action and relief of some of the extrapyramidal side effects experienced with typical antipsychotics. It has been found that D-amino acid oxidase, the enzyme that catalyses the breakdown of D-amino acids (e.g. D-alanine and D-serine — the neurotransmitters) is inhibited by risperidone. Risperidone acts on the following receptors: Dopamine receptors: This drug is an antagonist of the D1 (D1, and D5) as well as the D2 (D2, D3 and D4) family receptors, with 70-fold selectivity for the D2 family. It has "tight binding" properties, which means it has a long half-life. Like other antipsychotics, risperidone blocks the mesolimbic pathway, the prefrontal cortex limbic pathway, and the tuberoinfundibular pathway in the central nervous system. Risperidone may induce extrapyramidal side effects, akathisia and tremors, which is associated with diminished dopaminergic activity in the striatum.
=== January === 2 January – Three people are killed after a fire breaks out at the New County Hotel in Perth. 16 January Teachers in Scotland begin 16 days of "rolling" strike action, with strikes occurring in two local authorities each day, beginning with Glasgow and East Lothian. The UK government announces it will block the Gender Recognition Reform (Scotland) Bill amid concerns about its impact on UK-wide equality law. 23 January – A fire breaks out in former department store Jenners on Princes Street, Edinburgh, resulting in the death of a firefighter and the injury of four others. 24 January – Following a trial at the High Court of Glasgow, transgender woman Isla Bryson is convicted of raping two women in 2016 and 2019, the offences having been committed before she began gender reassignment therapy. She is remanded to Cornton Vale women's prison, but moved to HMP Edinburgh two days later after First Minister Nicola Sturgeon says Bryson will not be allowed to serve her sentence at Cornton Vale. 28 January – Following controversy over the Isla Bryson case, the Daily Record reports that Tiffany Scott, a trans woman subject to an Order for Lifelong Restriction for stalking a 13-year-old girl, has successfully applied for a transfer from a men's prison to a women's facility. The Scottish Conservatives urge the Scottish Government to halt the move. 29 January – The Scottish Prison Service pauses the movement of all transgender prisoners while it carries out an "urgent review" into the transgender cases held in its custody.
Poly(p-phenylene sulfide) (PPS) is synthesized by the reaction of sodium sulfide with p-dichlorobenzene in a polar solvent such as 1-methyl-2-pyrrolidinone (NMP). It is inherently flame-resistant and stable toward organic and aqueous conditions; however, it is somewhat susceptible to oxidants. Applications of PPS include automotive, microwave oven components, coatings for cookware when blended with fluorocarbon polymers, and protective coatings for valves, pipes, electromotive cells, etc.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.